Search - tctmd.com

Displaying 581 - 600 of 603

Sort: Relevancy | Date

News Daily News

尽管有战乱和冲突，但缺血性心脏病的死亡率仍然迎来了“阿拉伯之春”

Michael O'Riordan

August 26, 2016

News Daily News

Despite War and Strife, Ischemic Heart Disease Leads Deaths in ‘Arab Spring’

Michael O'Riordan

August 26, 2016

News Daily News

Improved Adherence to Medical Therapy Reduces CVD Events in Secondary Prevention Patients

Michael O'Riordan

August 16, 2016

News Daily News

AHA Makes Case for Palliative Care in Advanced Cardiovascular Disease and Stroke

Todd Neale

August 11, 2016

News Daily News

The Billions Spent on Healthcare for Sedentary Citizens Warrants Global Response

L.A. McKeown

July 28, 2016

News Daily News

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

Michael O'Riordan

June 30, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

News Daily News

备受争议的 LIGHT 试验现已发表，但未能证实 Contrave 的心血管风险

Michael O'Riordan

March 08, 2016

News Daily News

Optimal Risk Factor Control Translates Into Less Expenditure on Healthcare, Use of Resources

Michael O'Riordan

March 02, 2016

News Daily News

NEJM支持 Robert Califf担任FDA局长

L.A. McKeown

October 30, 2015

News Daily News

NEJM Endorses Robert Califf for FDA Commissioner

L.A. McKeown

October 30, 2015

News Daily News

NEJM Apoya a Robert Califf como Comisionado de la FDA

L.A. McKeown

October 30, 2015

News Daily News

No Money, No Drugs: Global Barriers to Secondary CVD Prevention

Caitlin E. Cox

October 27, 2015

News Daily News

美国的女性介入医生依然很罕见

Yael L. Maxwell

August 21, 2015

News Daily News

Las Mujeres Intervencionistas Siguen Siendo una Rareza en EE.UU.

Yael L. Maxwell

August 21, 2015

News Daily News

Female Interventionalists Remain a Rarity in the United States

Yael L. Maxwell

August 21, 2015

News Industry News

Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority

June 22, 2015

News Industry News

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

June 09, 2015

News Daily News

MI患者的低试验参与率引起了对适用性的质疑

Todd Neale

September 02, 2014

News Daily News

Low Trial Participation Rate of MI Patients Raises Questions of Applicability

Todd Neale

September 02, 2014

Advertisement

尽管有战乱和冲突，但缺血性心脏病的死亡率仍然迎来了“阿拉伯之春”

Despite War and Strife, Ischemic Heart Disease Leads Deaths in ‘Arab Spring’

Improved Adherence to Medical Therapy Reduces CVD Events in Secondary Prevention Patients

AHA Makes Case for Palliative Care in Advanced Cardiovascular Disease and Stroke

The Billions Spent on Healthcare for Sedentary Citizens Warrants Global Response

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

备受争议的 LIGHT 试验现已发表，但未能证实 Contrave 的心血管风险

Optimal Risk Factor Control Translates Into Less Expenditure on Healthcare, Use of Resources

NEJM支持 Robert Califf担任FDA局长

NEJM Endorses Robert Califf for FDA Commissioner

NEJM Apoya a Robert Califf como Comisionado de la FDA

No Money, No Drugs: Global Barriers to Secondary CVD Prevention

美国的女性介入医生依然很罕见

Las Mujeres Intervencionistas Siguen Siendo una Rareza en EE.UU.

Female Interventionalists Remain a Rarity in the United States

Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

MI患者的低试验参与率引起了对适用性的质疑

Low Trial Participation Rate of MI Patients Raises Questions of Applicability

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content